GFAP and COVID-19: It is interesting that previous studies that investigated the same biomarkers presented slightly different results, reporting the significant difference in NfL, GFAP, and TAU levels between survivors and deceased severe COVID-19 patients, but they did not observe the same to UCH-L1 levels [12, 28].